Abstract:
Background: Production of β-lactamase enzymes by Gram-negative bacteria (E coli ) is the
most common mechanism to acquire drug resistance to β-lactam antibiotics. Limitations in
detecting extended spectrum β-lactamases (ESBL) and Amp-C β-lactamases Metallo β-
lactamases have contributed to the uncontrolled spread of bacterial resistance and are of
significant clinical concern.
Objective : To detect ESBL, AmpC AND MBL among E coli isolates
Materials and Methods: A total of 104 isolates (E coli) were selected for detection of ESBL,
AmpC and MBL producers These isolates were phenotypically screened and confirmed by
confirmatory test by using the Kirby Bauer disk diffusion method.
Result: Among 104 isolates ( 80.8%) ESBL ( cefotaxime) producers, (12.5%) Ampc
(cefoxitin) producers, and (76.0%) were MBL producers , colistin showed (100% ) sensitive
followed by MEM(75%), IPM(74%), AN(65.4%),ETP(62.5%), AMC (60.5%), SFP (53.8%),
TZP(48.1%), TIC (48.1%), FOS (47.1%), CAZ (47.1%), TGC (46.2%), FT(36.4%), CRO
(31.7%), NOR (30.8%), FOX (27.9%), OFL (24%), CIP (22.1%), NA (20.2%), GM (19.2%),
FEP (16.3%), CFM (15.4%), AM (13.5%), CF (7.7%), CXM (1%).towards E coli
Conclusion : The present study highlights the necessity to identify the MDR β-lactamases stains
for effective therapy in severe as well as mild bacterial infections, thereby enabling to reduce the
risk of MDR in Tertiary care hospital and community settings. Further, similar studies in specific
geographical regions may be encouraged to have a brief idea of organism-based antibiotic
susceptibility patterns and β-lactamase production for effective management and treatment regimes Hence Early detection of β- lactamases among E coli avoid treatment failure and spread
of MDR
